Sanofi
POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFA AND OX40L

Abstract:

The present technology aims at providing a novel type of drug for treating a subject suffering from an autoimmune or inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to TNF.alpha. and at least two ISVDs binds to OX4OL. The present technology also provides nucleic acids, vectors and compositions.